GSK plc (GLAXF)
| Market Cap | 102.88B |
| Revenue (ttm) | 43.24B |
| Net Income (ttm) | 7.39B |
| Shares Out | n/a |
| EPS (ttm) | 1.79 |
| PE Ratio | 13.93 |
| Forward PE | 10.51 |
| Dividend | 0.84 (3.56%) |
| Ex-Dividend Date | Nov 13, 2025 |
| Volume | n/a |
| Average Volume | 1,320 |
| Open | 23.60 |
| Previous Close | 23.60 |
| Day's Range | 23.60 - 23.60 |
| 52-Week Range | 15.54 - 25.77 |
| Beta | 0.23 |
| RSI | 55.96 |
| Earnings Date | Feb 4, 2026 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2024, GSK plc's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.
Financial numbers in GBP Financial StatementsNews
GSK Downgraded to Underweight by Barclays Today | GSK Stock News
GSK Downgraded to Underweight by Barclays Today | GSK Stock News
FENI, BTI, GSK, HSBC: Large Inflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Fidelity Enhanced International ETF (Symbol: FENI) where we have detec...
GSK Wins Japan Approval for Exdensur(edit)
GSK Wins Japan Approval for Exdensur(edit)
US Cuts Childhood Vaccine Schedule To 11 Core Shots— What It Means For Vaccine Makers Like Merck And GSK
In a move that could impact vaccine-makers like Merck & Co. Inc. (NYSE: MRK), GSK plc (NYSE: GSK), the U.S. government has decided to massively reduce the number of vaccines it recommends for every ...
GSK Gains Approval for Exdensur in Japan for Asthma and CRSwNP Treatment
GSK Gains Approval for Exdensur in Japan for Asthma and CRSwNP Treatment
GSK (GSK) Gains Approval for Exdensur in Japan
GSK (GSK) Gains Approval for Exdensur in Japan
GlaxoSmithKline says Exdensur approved in Japan for severe asthma and CRSwNP
GSK's Exdensur Approved In Japan For Severe Asthma And CRSwNP
(RTTNews) - GSK plc (GSK, GSK.L) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Exdensur (depemokimab) for the treatment of bronchial asthma (limited to severe...
GSK (GSK) Gains Approval in China for COPD Treatment Nucala
GSK (GSK) Gains Approval in China for COPD Treatment Nucala
GSK Gains Approval in China for Nucala as COPD Treatment
GSK Gains Approval in China for Nucala as COPD Treatment
GlaxoSmithKline secures China approval for Nucala in adults with COPD
GSK's Nucala Approved In China For Adult COPD Treatment
(RTTNews) - GSK plc (GSK, GSK.L) announced that China's National Medical Products Administration (NMPA) has approved Nucala (mepolizumab) as add-on maintenance treatment of adult patients with inadequ...
Pfizer, GSK Lead U.S. Drugmakers Planning 2026 Price Hikes on 350 Drugs
Pfizer, GSK Lead U.S. Drugmakers Planning 2026 Price Hikes on 350 Drugs
GSK (GSK) Among Drugmakers Planning January Price Hikes for Medications
GSK (GSK) Among Drugmakers Planning January Price Hikes for Medications
Pfizer and GSK Lead 2026 U.S. Drug Price Hikes
Pfizer and GSK Lead 2026 U.S. Drug Price Hikes
Pfizer (PFE) and GSK (GSK) Plan Significant Drug Price Increases
Pfizer (PFE) and GSK (GSK) Plan Significant Drug Price Increases
Pfizer, GSK and other drugmakers eying U.S. price hikes for 350 medicines: report
Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump
Drugmakers plan to raise U.S. prices on at least 350 branded medications including vaccines against COVID, RSV and shingles and blockbuster cancer treatment Ibrance, even as the Trump administration p...
AstraZeneca's Lung Cancer Combo Falls Short In Phase 3 Trial
On Monday, AstraZeneca Plc (NASDAQ: AZN) released topline data from the LATIFY Phase 3 trial of ceralasertib in combination with Imfinzi (durvalumab). The trial did not meet the primary endpoint of o...
GSK To Lower Drug Prices
(RTTNews) - GSK plc (GSK, GSK.L) has entered into an agreement with the U.S. Administration to lower the cost of prescription medicines for American patients, including GSK's respiratory portfolio. GS...
Samsung Biologics acquires Human Genome Sciences from GSK
Samsung Biologics To Acquire GSK's Rockville Facility For US$280 Mln
(RTTNews) - Samsung Biologics (207940.KS) announced that its wholly owned U.S. subsidiary, Samsung Biologics America, will acquire 100% of Human Genome Sciences from GSK (GSK, GSK.L) for US$280 millio...
Samsung Biologics to Acquire Human Genome Sciences from GSK
Samsung Biologics to Acquire Human Genome Sciences from GSK
Samsung Biologics to buy U.S. drug production facility from GSK for $280 mln
South Korea's Samsung Biologics said on Monday its U.S. unit is buying a U.S. drug production facility from GSK for $280 million.